These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 11251655)

  • 21. Laboratory diagnosis of bleeding disorders. Basic screening tests.
    Palmer RL
    Postgrad Med; 1984 Dec; 76(8):137-42, 147-8. PubMed ID: 6334288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor.
    Ng C; Silliman CC; Pearl G; Smith W; Manco-Johnson M; Wang M
    Pediatr Blood Cancer; 2013 Jul; 60(7):E23-5. PubMed ID: 23382082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgM anticoagulant with acquired abnormalities in factor VIII.
    Andes WA
    Thromb Res; 1982 Sep; 27(6):703-12. PubMed ID: 6817451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired factor VIII inhibitors in nonhemophilic patients.
    Söhngen D; Specker C; Bach D; Kuntz BM; Burk M; Aul C; Kobbe G; Heyll A; Hollmig KA; Schneider W
    Ann Hematol; 1997 Feb; 74(2):89-93. PubMed ID: 9063379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate.
    Punzalan RC; Gottschall JL
    Transfus Med Rev; 2016 Oct; 30(4):189-96. PubMed ID: 27576087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors to clotting factors.
    Sallah S
    Ann Hematol; 1997; 75(1-2):1-7. PubMed ID: 9322677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options.
    Livnat T; Zivelin A; Tamarin I; Guetta V; Salomon O
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):661-6. PubMed ID: 19730246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation.
    Stableforth P; Tamagnini GL; Dormandy KM
    Br J Haematol; 1976 Aug; 33(4):565-73. PubMed ID: 1087568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
    Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
    Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The factor VIII complex: hemophilia A and von Willebrand disease].
    Tobelem G; Rothschild C
    Sem Hop; 1982 Sep; 58(35):2032-6. PubMed ID: 6293093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.
    Tang M; Fenger-Eriksen C; Wierup P; Greisen J; Ingerslev J; Hjortdal V; Sørensen B
    Thromb Res; 2017 Jun; 154():73-79. PubMed ID: 28437748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR; Kevy SV
    Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Severe Acquired Haemophilia A with Immunosuppressive Agent: A Case Report of One Patient.
    Škunca Ž; Peraica AP
    Coll Antropol; 2016 Jun; 40(2):139-43. PubMed ID: 29139630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H
    Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.